Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 611,472	$ 216,186
Accounts receivable, net		121
Insurance receivable	25,000
Inventories	5,345	0
Available-for-sale securities	16,499	49,997
Prepaid research and development expenses	2,853	6,427
Deposit on inventory	31,818
Other current assets	5,911	6,679
Total current assets	698,898	279,410
Property and equipment, net	4,070	4,440
Intangible assets, net	19,932	21,047
Goodwill	64,253	57,192
Other assets	18,206	2,468
Total assets	805,359	364,557
Current liabilities:
Accounts payable	14,308	10,912
Accrued research and development expenses	21,344	35,198
Deferred revenue	2,755
Milestone liability	21,511	20,062
Accrued liability for legal settlement	142,000
Other accrued expenses	17,467	19,487
Total current liabilities	219,385	85,659
Deferred income taxes, net	421	0
Convertible senior notes	282,082	281,126
Deferred rent, long-term	4,282	1,406
Total liabilities	506,170	368,191
Commitments and contingencies (Note 14)
Stockholders' equity (deficit):
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2017 and December 31, 2016
Common stock, $0.001 par value per share, 100,000,000 shares authorized at September 30, 2017 and December 31, 2016; 49,002,468 and 38,724,090 shares issued and outstanding at September 30, 2017 and December 31, 2016 respectively	49	39
Additional paid-in capital	1,767,397	1,174,950
Accumulated other comprehensive loss	(42,701)	(47,580)
Accumulated deficit	(1,425,556)	(1,131,043)
Total stockholders' equity (deficit)	299,189	(3,634)
Total liabilities and stockholders' equity (deficit)	$ 805,359	$ 364,557